GlassScriptPhysician profile
Jeffrey A Lynn
NPI 1831117043
$895.32
in general payments reported to CMS, 2019-2025
15 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.53 · 2022: $200 · 2023: $160 · 2024: $122 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $227.79 | 2022-2025 | Nuzyra |
| Biocomposites INC | $147.90 | 2025 | Stimulan |
| Ani Pharmaceuticals, INC. | $116.20 | 2024-2025 | Purified Cortrophin Gel |
| Angiodynamics, INC. | $113.06 | 2022 | |
| Nevro Corp. | $65.82 | 2023 | Senza |
| Nabriva Therapeutics, Plc | $49.91 | 2022 | |
| Melinta Therapeutics, LLC | $40.53 | 2019 | |
| Smith+Nephew, INC. | $28.50 | 2025 | Renasys Go V2 Home |
| Vertex Pharmaceuticals Incorporated | $18.47 | 2025 | |
| Medtronic, INC. | $17.29 | 2025 | Inceptiv |
| Amgen INC. | $16.26 | 2025 | Krystexxa |
| Paragon 28, INC. | $14.03 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.73 | 2023 | Jublia |
| Kowa Pharmaceuticals America, INC. | $13.42 | 2023 | Seglentis |
| Organogenesis INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.